China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Resources Double-Crane Pharmaceutical Co Ltd
Free Cash Flow
China Resources Double-Crane Pharmaceutical Co Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
|
Free Cash Flow
¥869.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Free Cash Flow
¥4.5B
|
CAGR 3-Years
22%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Free Cash Flow
¥8.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
46%
|
CAGR 10-Years
16%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Free Cash Flow
¥4.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Free Cash Flow
¥6.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Free Cash Flow
¥4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
256%
|
CAGR 10-Years
N/A
|
|
China Resources Double-Crane Pharmaceutical Co Ltd
Glance View
In the dynamic landscape of China's pharmaceutical industry, China Resources Double-Crane Pharmaceutical Co Ltd emerges as a key player. It traces its roots back to the early 20th century, embodying a rich history of transformation and innovation. The company seamlessly integrates research, development, production, and sales, making it a formidable force in the healthcare sector. Primarily, it focuses on the production of chemical and biological drugs, catering to a wide range of therapeutic areas such as cardiovascular diseases, anti-infection solutions, and nutritional drugs. Through its comprehensive network, the company not only retains a robust domestic presence but also pushes its products into international markets, driving its revenue growth. Double-Crane's business model thrives on a blend of strategic partnerships and a strong emphasis on R&D. By collaborating with top research institutes and leveraging cutting-edge technology, it innovates new products to meet the rising demands of modern healthcare. The company’s substantial investment in R&D has allowed it to build a strong pipeline of proprietary drugs, ensuring a steady stream of products to boost its market position. With a keen eye on market trends and patient needs, China Resources Double-Crane continually optimizes its production processes and expands its distribution channels. This methodical approach enables the company to enhance its profitability while propelling it as a leader in the pharmaceutical industry.
See Also
What is China Resources Double-Crane Pharmaceutical Co Ltd's Free Cash Flow?
Free Cash Flow
869.9m
CNY
Based on the financial report for Dec 31, 2025, China Resources Double-Crane Pharmaceutical Co Ltd's Free Cash Flow amounts to 869.9m CNY.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
5%
Over the last year, the Free Cash Flow growth was -27%. The average annual Free Cash Flow growth rates for China Resources Double-Crane Pharmaceutical Co Ltd have been -1% over the past three years , -3% over the past five years , and 5% over the past ten years .